Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus - Université de Lorraine Access content directly
Journal Articles Autoimmunity Reviews Year : 2021

Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus

Ailsa Hart
  • Function : Author
Sameer Al Awadhi
  • Function : Author
Ernest Choy
  • Function : Author

Abstract

Several efforts have been made to improve the available therapeutic armamentarium of patients with immune-mediated inflammatory disorders (IMIDs) leading to the development of biobetters. To date, there is no commonly accepted definition of biobetters. Sixteen physicians with expertise in the field of IMIDs from eleven countries attended a virtual international consensus meeting to provide for the first time a definition of biobetter and to identify unmet needs on this topic. Improvements in clinical outcomes and drug pharmacology were considered crucial for the definition of biobetters, while safety profile and patient acceptability were not. In addition, an appropriate balance between clinical outcomes and costs and a shared decision between physicians and patients should guide the decision to use a biobetter. Clinical studies are required to validate the biobetter definition and to investigate their role in the management of patients with IMIDs.

Dates and versions

hal-04214627 , version 1 (22-09-2023)

Identifiers

Cite

Ferdinando d'Amico, Virginia Solitano, Daniel Aletaha, Ailsa Hart, Fernando Magro, et al.. Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmunity Reviews, 2021, 20 (7), pp.102849. ⟨10.1016/j.autrev.2021.102849⟩. ⟨hal-04214627⟩
5 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More